CytomX Therapeutics, Inc. (NASDAQ:CTMX) enjoyed a 95.43% run-up in share price since hitting record low of $9.85. The stock managed 5.94% rise and now stands at $19.25 as of Oct. 2, 2017. At recent session, the prices were hovering between $18.1 and $19.46. This company shares are 46.75% off its target price of $28.25 and the current market capitalization stands at $705.71M. The recent change has given its price a 23.33% lead over SMA 50 and -3.85% deficit over its 52-week high. The stock witnessed 11.4% gains, 21.37% gains and 13.1% gains for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found CTMX’s volatility during a week at 4.52% and during a month it has been found around 4.53%.CytomX Therapeutics, Inc. (CTMX) Top Holders
Institutional investors currently hold around $480 million or 76% in CTMX stock. Look at its top three institutional owners. Fmr Llc owns $100.16 million in CytomX Therapeutics, Inc., which represents roughly 14.19% of the company’s market cap and approximately 20.87% of the institutional ownership. Similar statistics are true for the second largest owner, Canaan Partners Ix Llc, which owns 4,244,381 shares of the stock are valued at $77.12 million. The third largest holder is Bvf Inc/Il, which currently holds $36.83 million worth of this stock and that ownership represents nearly 5.22% of its market capitalization.CytomX Therapeutics, Inc. 13F Filings
At the end of 06/30/2017 reporting period, 61 institutional holders increased their position in CytomX Therapeutics, Inc. (NASDAQ:CTMX) by some 4,023,015 shares, 30 decreased positions by 1,097,178 and 17 held positions by 21,316,019. That puts total institutional holdings at 26,436,212 shares, according to SEC filings. The stock grabbed 19 new institutional investments totaling 1,072,674 shares while 15 institutional investors sold out their entire positions totaling 408,643 shares.CytomX Therapeutics, Inc. (NASDAQ:CTMX) Insider Trades
Multiple company employees have indulged in significant insider trading. CytomX Therapeutics, Inc. disclosed in a document filed with the US Securities and Exchange Commission (SEC) that Director Gluck Frederick W has sold 5,000 shares of CytomX Therapeutics, Inc. (CTMX) in trading session dated Sep. 26, 2017. These shares are worth $86,500 and were traded at $17.3 each. The SEC filing shows that Tepper Robert I performed a sale of 20,000 shares. The 10% Owner disposed these shares by way of transaction on Sep. 19, 2017. The company’s shares were given away at $18 per share worth to an income of some $360,000 on account of Tepper Robert I.
President and CEO, Mccarthy Sean A., sold 9,930 common shares of CytomX Therapeutics, Inc. (CTMX) in the open market. In a transaction dated Sep. 01, 2017, the shares were put up for sale at an average price of $17.33, raking in a sum of $172,087. After this sale, 162,982 common shares of CTMX are directly owned by the insider, with total stake valued at $3,137,404.
In the transaction dated Sep. 01, 2017, the great number of shares disposed came courtesy the President and CEO; Mccarthy Sean A. disposed a total of 9,930 shares at an average price of $17.32, amounting to approximately $171,988. The insider now directly owns 162,982 shares worth $3,137,404.CytomX Therapeutics, Inc. (CTMX) Analyst Guide
Several analysts have released their opinion on CytomX Therapeutics, Inc. (NASDAQ:CTMX), with 4 analysts believing it is a strong buy. Whereas 1 of them predict the stock is a hold. Also, there are 0 buy, 0 sell and 0 strong sell ratings, collectively assigning a 1.4 average brokerage recommendation.